Clinical trial
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From…
NCT04626674 · Sarepta Therapeutics, Inc., Industry · Recruiting
Key facts
| NCT number | NCT04626674 |
|---|---|
| Title | A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) |
| Official title | An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression From SRP-9001 in Subjects With Duchenne Muscular Dystrophy (ENDEAVOR) |
| Acronym | ENDEAVOR |
| Lead sponsor | Sarepta Therapeutics, Inc., Industry |
| Collaborators | Hoffmann-La Roche Industry |
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Muscular Dystrophy, Duchenne |
| Intervention type | Genetic |
| Interventions | delandistrogene moxeparvovec |
| Enrollment | 83 |
| Start date | Nov 23, 2020 |
| Primary completion | Dec 31, 2027 |
| Completion | Feb 29, 2028 |
| First posted | Nov 12, 2020 |
| Last update posted | Dec 29, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: